Denosumab biosimilar is under clinical development by Sandoz Group and currently in Pre-Registration for Giant Cell Tumor Of Bone.
Novartis strikes radiopharma deal with Ratio worth up to $745M
Novartis is making another pact in radiopharma, promising as much as $745 million to a Boston-based startup. Ratio Therapeutics will get an undisclosed upfront payment